Research programme: antifibrotics - Blade Therapeutics

Drug Profile

Research programme: antifibrotics - Blade Therapeutics

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Blade Therapeutics
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Cysteine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis

Most Recent Events

  • 18 Oct 2017 Blade Therapeutics intends to initiate clinical development for its lead candidate in mid 2018
  • 24 Jun 2017 Preclinical trials in Fibrosis in USA (unspecified route) (Blade Therapeutics website, June 2017)
  • 20 Jun 2017 Blade Therapeutics plans IND-enabling studies for Fibrosis by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top